CTLA4 and pancreatic adenocarcinoma: In fact, clinical studies of combination therapies of anti-PD-1 (nivolumab) or anti-CTLA-4 (ipilimumab) with cancer vaccines provided improved response rates in melanoma and pancreatic adenocarcinoma compared with anti-PD-1 or anti-CTLA-4 alone [190,191,192,193,194].